ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,084.61
-0.26%
Dow Jones
42,948.78
1.43%
Gold vs US Dollar
2,626.70
1.27%
Brent Oil
72.695
0.43%
Bitcoin
96,962.65
-0.51%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Xilio Therapeutics Inc (XLO) Share Price

XLO Xilio Therapeutics Inc

1.125
0.187 (19.94%)
Last Updated: 20:02:11
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Xilio Therapeutics Inc NASDAQ:XLO NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.187 19.94 1.125 1.12 1.13 1.16 0.8364 1.06 5,894,197 20:02:11   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -76.4M -1.7381 -0.66 41.23M
 Type  Size  Price  Time  Units 
  404 1.125 20:02:13 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore XLO News
19/12/202412:45EDGAR2Form 8-K - Current report
19/12/202412:30GLOBEXilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI 
16/12/202412:30GLOBEXilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
03/12/202421:30GLOBEXilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/202414:25EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202414:20EDGAR2Form 8-K - Current report
07/11/202414:15GLOBEXilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Period
Draw mode
Data Downloads for XLO

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Xilio Therapeutics Inc Articles

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads